Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoldonrasib + daraxonrasib
- Development stage
- Unknown
- Lead developer
- REVOLUTION Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zoldonrasib + daraxonrasib is an investigational combination therapy developed by Revolution Medicines, consisting of two distinct RAS(ON) inhibitors. Zoldonrasib (RMC-9805) is an oral, tri-complex, covalent inhibitor that selectively targets the active (ON) state of the KRAS G12D mutation. Daraxonrasib (RMC-6236) is a multi-selective, noncovalent RAS(ON) inhibitor designed to inhibit a broad spectrum of RAS mutations. By combining a mutation-selective inhibitor with a multi-RAS inhibitor, the regimen aims to maximize therapeutic pressure on RAS signaling and prevent or overcome resistance in patients with KRAS G12D-mutant advanced solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).
- Brand names
- RMC-9805RMC9805RMC 9805RMC-6236RMC6236RMC 6236
- Other names
- RMC-9805 and RMC-6236 combinationRMC9805 and RMC-6236 combinationRMC 9805 and RMC-6236 combinationRAS(ON) inhibitor doublet
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)HRAS (H-Ras protein)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on zoldonrasib + daraxonrasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoldonrasib + daraxonrasib.